Cargando…
Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany
BACKGROUND: Randomised controlled trials showed human papillomavirus (HPV)-based screening leads to a significant reduction in cervical cancer incidence compared with cytology-based screening only. METHODS: Non-hysterectomised participants ≥30 years underwent co-testing with Papanicolaou (Pap) smear...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734660/ https://www.ncbi.nlm.nih.gov/pubmed/30988395 http://dx.doi.org/10.1038/s41416-019-0453-2 |
_version_ | 1783450190199390208 |
---|---|
author | Horn, Johannes Denecke, Agnieszka Luyten, Alexander Rothe, Beate Reinecke-Lüthge, Axel Mikolajczyk, Rafael Petry, Karl Ulrich |
author_facet | Horn, Johannes Denecke, Agnieszka Luyten, Alexander Rothe, Beate Reinecke-Lüthge, Axel Mikolajczyk, Rafael Petry, Karl Ulrich |
author_sort | Horn, Johannes |
collection | PubMed |
description | BACKGROUND: Randomised controlled trials showed human papillomavirus (HPV)-based screening leads to a significant reduction in cervical cancer incidence compared with cytology-based screening only. METHODS: Non-hysterectomised participants ≥30 years underwent co-testing with Papanicolaou (Pap) smear and HR-HPV testing (Hybrid Capture 2; HC2). Women with normal findings had their next screening round after 5 years, and HC2+ and Pap abnormal cases were immediately referred for colposcopy, while cases with discordant findings had repeat testing after 12 months with referral to colposcopy in cases with persistent positive findings. RESULTS: Twenty-six thousand six hundred and twenty-four women were recruited between February 2006 and December 2016. Two hundred and seventy-four CIN3+ cases were diagnosed (270 HPV+, 4 HPV−), including 31 invasive cervical cancers (29 HPV+, 2 HPV−). No CIN3+ was detected in HPV− women with abnormal cytology. We observed a significant decline in the 5-year incidence of CIN3+ (from 0.96% [95% CI 0.85–1.09%] to 0.16% [95% CI 0.10–0.25%]; p < 0.0001) and cervical cancer (from 0.10% [95% CI 0.07%–0.15%] to 0.025% [95% CI 0.01–0.08%]; p = 0.01) between the first and subsequent rounds. Approximately 90% (246/274) of CIN3+ cases were diagnosed at first colposcopy. CONCLUSIONS: The decline in disease rates with 5-yearly co-testing seems mainly attributable to HPV testing since no CIN3+ occurred in HPV−/Pap+ women. |
format | Online Article Text |
id | pubmed-6734660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67346602020-01-22 Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany Horn, Johannes Denecke, Agnieszka Luyten, Alexander Rothe, Beate Reinecke-Lüthge, Axel Mikolajczyk, Rafael Petry, Karl Ulrich Br J Cancer Article BACKGROUND: Randomised controlled trials showed human papillomavirus (HPV)-based screening leads to a significant reduction in cervical cancer incidence compared with cytology-based screening only. METHODS: Non-hysterectomised participants ≥30 years underwent co-testing with Papanicolaou (Pap) smear and HR-HPV testing (Hybrid Capture 2; HC2). Women with normal findings had their next screening round after 5 years, and HC2+ and Pap abnormal cases were immediately referred for colposcopy, while cases with discordant findings had repeat testing after 12 months with referral to colposcopy in cases with persistent positive findings. RESULTS: Twenty-six thousand six hundred and twenty-four women were recruited between February 2006 and December 2016. Two hundred and seventy-four CIN3+ cases were diagnosed (270 HPV+, 4 HPV−), including 31 invasive cervical cancers (29 HPV+, 2 HPV−). No CIN3+ was detected in HPV− women with abnormal cytology. We observed a significant decline in the 5-year incidence of CIN3+ (from 0.96% [95% CI 0.85–1.09%] to 0.16% [95% CI 0.10–0.25%]; p < 0.0001) and cervical cancer (from 0.10% [95% CI 0.07%–0.15%] to 0.025% [95% CI 0.01–0.08%]; p = 0.01) between the first and subsequent rounds. Approximately 90% (246/274) of CIN3+ cases were diagnosed at first colposcopy. CONCLUSIONS: The decline in disease rates with 5-yearly co-testing seems mainly attributable to HPV testing since no CIN3+ occurred in HPV−/Pap+ women. Nature Publishing Group UK 2019-04-16 2019-05-14 /pmc/articles/PMC6734660/ /pubmed/30988395 http://dx.doi.org/10.1038/s41416-019-0453-2 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Horn, Johannes Denecke, Agnieszka Luyten, Alexander Rothe, Beate Reinecke-Lüthge, Axel Mikolajczyk, Rafael Petry, Karl Ulrich Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany |
title | Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany |
title_full | Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany |
title_fullStr | Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany |
title_full_unstemmed | Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany |
title_short | Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany |
title_sort | reduction of cervical cancer incidence within a primary hpv screening pilot project (wolphscreen) in wolfsburg, germany |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734660/ https://www.ncbi.nlm.nih.gov/pubmed/30988395 http://dx.doi.org/10.1038/s41416-019-0453-2 |
work_keys_str_mv | AT hornjohannes reductionofcervicalcancerincidencewithinaprimaryhpvscreeningpilotprojectwolphscreeninwolfsburggermany AT deneckeagnieszka reductionofcervicalcancerincidencewithinaprimaryhpvscreeningpilotprojectwolphscreeninwolfsburggermany AT luytenalexander reductionofcervicalcancerincidencewithinaprimaryhpvscreeningpilotprojectwolphscreeninwolfsburggermany AT rothebeate reductionofcervicalcancerincidencewithinaprimaryhpvscreeningpilotprojectwolphscreeninwolfsburggermany AT reineckeluthgeaxel reductionofcervicalcancerincidencewithinaprimaryhpvscreeningpilotprojectwolphscreeninwolfsburggermany AT mikolajczykrafael reductionofcervicalcancerincidencewithinaprimaryhpvscreeningpilotprojectwolphscreeninwolfsburggermany AT petrykarlulrich reductionofcervicalcancerincidencewithinaprimaryhpvscreeningpilotprojectwolphscreeninwolfsburggermany |